GLP-1RAs are approved by the U.S. Food and Drug Administration for managing type 2 diabetes and obesity through multiple mechanisms, including enhanced insulin secretion, glucagon suppression, delayed gastric emptying, and modulation of central appetite pathways [98]. The gene discussed is INS; the disease is type 2 diabetes mellitus.